Novartis announced a restructuring plan yesterday which involves cutting between 400 - 440 development jobs in Switzerland over the next few years.
Another 240 jobs are at risk in the USA.
The Basel-based pharmaceutical company currently employs over 10’000 people, around 3’000 of whom are dedicated to development.
The company, which is consistently ranked as one of the global top 5 pharmaceutical companies in the world, insists that its research activities will remain unaffected.
Arms makers leaving Switzerland
Army worried about using Microsoft servers
Man shot in Annemasse
Violence against train staff at 'alarming' levels
Russian singer faces controversy
Geneva could ban terrace smoking during meal times
